{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacogenomic+Studies",
    "query": {
      "intervention": "Pharmacogenomic Studies"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 309,
    "total_pages": 31,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacogenomic+Studies&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-20T19:04:09.532Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03300557",
      "title": "Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atypical Hyperplasia",
        "Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia",
        "Endometrial Carcinoma",
        "FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma",
        "FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacokinetic Study",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "45 Years and older · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2017-11-15",
      "completion_date": "2025-08-14",
      "has_results": true,
      "last_update_posted_date": "2025-08-29",
      "last_synced_at": "2026-09-20T19:04:09.532Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Minneapolis, Minnesota • Madison, Wisconsin",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03300557"
    },
    {
      "nct_id": "NCT05656469",
      "title": "Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mood Disorders",
        "Anxiety Disorders",
        "Psychotic Disorders"
      ],
      "interventions": [
        {
          "name": "Personalised medication advice based on pharmacogenetic testing",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Parnassia Groep",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "16 Years to 70 Years"
      },
      "enrollment_count": 2500,
      "start_date": "2023-02-23",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-09-20T19:04:09.532Z",
      "location_count": 1,
      "location_summary": "Syracuse, New York",
      "locations": [
        {
          "city": "Syracuse",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05656469"
    },
    {
      "nct_id": "NCT03005080",
      "title": "Pharmacogenetic Testing in Children With Persistent Gastroesophageal Reflux Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Gastroesophageal Reflux"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 51,
      "start_date": "2016-12",
      "completion_date": "2018-10",
      "has_results": false,
      "last_update_posted_date": "2019-04-09",
      "last_synced_at": "2026-09-20T19:04:09.532Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03005080"
    },
    {
      "nct_id": "NCT07145333",
      "title": "Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "SCLC"
      ],
      "interventions": [
        {
          "name": "Topotecan - usual",
          "type": "DRUG"
        },
        {
          "name": "Topotecan - study",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "24 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "24 Years to 64 Years"
      },
      "enrollment_count": 600,
      "start_date": "2025-08-12",
      "completion_date": "2026-10-28",
      "has_results": false,
      "last_update_posted_date": "2025-09-08",
      "last_synced_at": "2026-09-20T19:04:09.532Z",
      "location_count": 1,
      "location_summary": "Rockville, Maryland",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07145333"
    },
    {
      "nct_id": "NCT02378220",
      "title": "Pharmacogenetic Testing Among Home Health Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Adverse Drug Events",
        "Adverse Drug Reactions",
        "Drug Interaction Potentiation",
        "Drug Metabolism, Poor, CYP2D6-RELATED",
        "Drug Metabolism, Poor, CYP2C19-RELATED",
        "Cytochrome P450 Enzyme Deficiency",
        "Cytochrome P450 CYP2D6 Enzyme Deficiency",
        "Cytochrome P450 CYP2C9 Enzyme Deficiency",
        "Cytochrome P450 CYP2C19 Enzyme Deficiency",
        "Cytochrome P450 CYP3A Enzyme Deficiency",
        "Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant",
        "Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant",
        "Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant"
      ],
      "interventions": [
        {
          "name": "Pharmacogenetic testing",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Genelex Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2015-03",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2019-09-20",
      "last_synced_at": "2026-09-20T19:04:09.532Z",
      "location_count": 1,
      "location_summary": "Searcy, Arkansas",
      "locations": [
        {
          "city": "Searcy",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02378220"
    },
    {
      "nct_id": "NCT01886404",
      "title": "EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Efavirenz",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2013-12-01",
      "completion_date": "2014-08-01",
      "has_results": false,
      "last_update_posted_date": "2023-12-12",
      "last_synced_at": "2026-09-20T19:04:09.532Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01886404"
    },
    {
      "nct_id": "NCT02297126",
      "title": "A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Adverse Drug Reaction"
      ],
      "interventions": [
        {
          "name": "Pharmacogenetic Intervention Arm (pharmacogenetic testing)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4465,
      "start_date": "2015-03",
      "completion_date": "2019-05-03",
      "has_results": false,
      "last_update_posted_date": "2021-01-08",
      "last_synced_at": "2026-09-20T19:04:09.532Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02297126"
    },
    {
      "nct_id": "NCT03552796",
      "title": "sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Bladder Carcinoma",
        "Bladder Cancer Stage 0",
        "Bladder Cancer Stage I"
      ],
      "interventions": [
        {
          "name": "Pharmacokinetic Study",
          "type": "OTHER"
        },
        {
          "name": "Recombinant EphB4-HSA Fusion Protein",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-08-01",
      "completion_date": "2025-08-01",
      "has_results": false,
      "last_update_posted_date": "2023-06-26",
      "last_synced_at": "2026-09-20T19:04:09.532Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03552796"
    },
    {
      "nct_id": "NCT04645004",
      "title": "Antenatal Platelet Response on Aspirin: a Pharmacokinetic Study Through Pregnancy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Preeclampsia"
      ],
      "interventions": [
        {
          "name": "Aspirin 81Mg Non-enteric coated Tab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "13 Years to 55 Years · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2020-12-29",
      "completion_date": "2024-03-15",
      "has_results": false,
      "last_update_posted_date": "2024-04-18",
      "last_synced_at": "2026-09-20T19:04:09.532Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04645004"
    },
    {
      "nct_id": "NCT05762744",
      "title": "Pharmacogenomics of GLP1 Receptor Agonists",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Exenatide Injection (before the first FSIGT)",
          "type": "DRUG"
        },
        {
          "name": "Exenatide injection before the second FSIGT)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2016-06-01",
      "completion_date": "2022-10-31",
      "has_results": true,
      "last_update_posted_date": "2025-07-01",
      "last_synced_at": "2026-09-20T19:04:09.532Z",
      "location_count": 1,
      "location_summary": "Lancaster, Pennsylvania",
      "locations": [
        {
          "city": "Lancaster",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05762744"
    }
  ]
}